A Multinational, Randomized, Phase III Study of XELIRI with/without Bevacizumab versus FOLFIRI with/without Bevacizumab as Second-line Therapy in Patients with Metastatic Colorectal Cancer
Phase of Trial: Phase III
Latest Information Update: 26 Feb 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine; Fluorouracil; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colorectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms AXEPT
- 19 Jan 2019 Results (n=642) presented at the 2019 Gastrointestinal Cancers Symposium.
- 06 Jan 2019 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated